Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Mason J HandfordChemical Physiology and Biochemistry Department, Oregon Health & Science University, 3181 SW Sam Jackson Boulevard, Portland, Oregon 97239, United States.ORCID 0000-0001-6764-3893
Yuexin LiPortland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Teresa RiscoePortland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Katherine M LiebmanPortland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Xiaowei ZhangPortland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Jane X KellyPortland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0001-8871-0207
Michael K RiscoePortland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-1343-5279
Funding
Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0M
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2M
Next Generation ELQs for Treatment and Once-Monthly Protection Against MalariaR01AI182513 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE, AKHIL B VAIDYA · 2025 to 2026
$1.2M
Next Generation ELQs for Treatment and Once-Monthly Protection Against MalariaR56AI182513 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN, VAIDYA, AKHIL B · 2024 to 2024
$687k
BLRD VA I01 BX001421BLRD VA I01 BX003312BLRD VA IK6 BX004857NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI141412NIAID NIH HHS R01 AI182513NIAID NIH HHS R56 AI182513
6 · The paper itself
Abstract
A structure activity relationship study was conducted to optimize metabolic stability and in vivo activity of amodiaquine analog antimalarials. Antiplasmodial activity of synthesized amodiachins (ADCs) were evaluated against drug-sensitive and drug-resistant strains of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of Amodiachins, a Novel Class of 4-Aminoquinoline Antimalarials Active against Multidrug-Resistant · full record | OpenQuestion